A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 464
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DR5
Long Form : death receptor 5
No. Year Title Co-occurring Abbreviation
1997 Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. DcR1
1997 Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. ---
2001 Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. ---
2001 TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. DEX, DOX, MM, NF, TNF
2002 Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. NSAIDs
2002 Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. ER, TG
2002 Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. FLIP, TRAIL
2002 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. FADD, HEK, NF-kappaB, NIK, RIP, TRAIL
2003 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. TRAIL
10  2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. ---
11  2003 Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. DCA, TRAIL-R2
12  2003 CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. DPP-IV
13  2003 TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. TRAIL
14  2004 Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. CI, NSCLC
15  2004 Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. VEGF
16  2004 Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. CD178, CHO, CLL, CTLs, TNF
17  2004 Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. HDACIs, SAHA, TRAIL, TSA
18  2004 The p53 protein influences the sensitivity of testicular germ cells to mono-(2-ethylhexyl) phthalate-induced apoptosis by increasing the membrane levels of Fas and DR5 and decreasing the intracellular amount of c-FLIP. MEHP
19  2004 [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells]. TRAIL
20  2004 [Involvement of apoptosis and proinflammatory cytokines in the pathogenesis of anemia in multiple myeloma]. EPO, IFN-gamma, TNF, TRAIL
21  2005 1'-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL. ACA
22  2005 Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. DR4, NF-kappaB
23  2005 CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. gp120, HAART, IFN, PBMCs, TNF
24  2005 Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). ROS, TRAIL
25  2005 Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. DR4, TRAIL
26  2005 Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. ---
27  2005 Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. CHOP, TRAIL
28  2005 Short incubation with 2-methoxyestradiol kills malignant glioma cells independent of death receptor 5 upregulation. 2-ME, MTT
29  2005 The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. TRAIL
30  2005 The two faces of NFkappaB in cell survival responses. HDAC1
31  2005 Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. DR4, TRAIL
32  2006 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. PPARgamma, TRAIL
33  2006 A comprehensive study of p53 transcriptional activity in thymus and spleen of gamma irradiated mouse: high sensitivity of genes involved in the two main apoptotic pathways. ---
34  2006 Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. SAHA, TRAIL
35  2006 Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis? PBMC, pDC
36  2006 Construction and characterization of a pseudo-immune human antibody library using yeast surface display. scFv
37  2006 ESE-3 transcription factor is involved in the expression of death receptor (DR)-5 through putative Ets sites. DR, TRAIL
38  2006 HIV-1 immunopathogenesis: how good interferon turns bad. AIDS, HIV-1, IFN-alpha, pDC, TRAIL
39  2006 Hypoxia/reoxygenation up-regulated the expression of death receptor 5 and enhanced apoptosis in human hepatocyte line. IRI, TRAIL
40  2006 Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells. pDC
41  2006 Molecular mechanisms of GD3-induced apoptosis in U-1242 MG glioma cells. FADD, TNFR1
42  2006 PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. PPARgamma, TRAIL
43  2006 Protective effects of neurotrophic factors on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of murine adrenal chromaffin cell line tsAM5D. GDNF, TRAIL
44  2006 Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. SFN, TRAIL
45  2006 Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. COX-2
46  2006 The clinical trail of TRAIL. DR4, TRAIL
47  2006 The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. TRAIL
48  2006 TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. ATO, FLIP, PI3K, TRAIL
49  2006 TRAIL-induced apoptosis in U-1242 MG glioma cells. FasR, TNFR1, TRAIL
50  2007 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells. CHOP, NAG1
51  2007 Brain-derived neurotrophic factor suppresses tunicamycin-induced upregulation of CHOP in neurons. ATF6, BDNF, ER, GADD153, UPR
52  2007 Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. COX-2, TRAIL
53  2007 DR5 activation of caspase-8 induces DC maturation and immune enhancement in vivo. CASP8, TNFR
54  2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. IHC
55  2007 Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition. EA, EABE, HPLC
56  2007 Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. CHOP
57  2007 Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. DR4, FFA, JNK
58  2007 Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. ACATN, ALS, CCNC, DCTN1, EGR3, pNfH
59  2007 Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. TRAIL
60  2007 Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. TRAIL
61  2007 Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. NDGA, TRAIL
62  2007 RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. gammaT, TRAIL
63  2007 Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. IAP, PARP, PEL, ROS, tBid
64  2007 Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. DR4, TRAIL
65  2007 Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. 8-Cl-Ado, ChIP, DR4, EMSA, NF-kappaB, TRAIL
66  2007 The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study. TNFR
67  2007 The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. CHOP, FTIs
68  2007 The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. FTI, siRNA, TRAIL
69  2007 The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. NSCLC, siRNA, TRAIL
70  2007 TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. ---
71  2007 [Gene expression profile of spinal ventral horn in ALS]. ACATN, ALS, CCNC, DCTN1, EGR3, NFKB
72  2007 [Study of molecular mechanism of doxorubicin enhancement of TRAIL, inducing apoptosis of myeloma cell line KM3]. TRAIL
73  2008 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. CHOP, ROS
74  2008 A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. ---
75  2008 Acute effects of haemodialysis on pro-/anti- apoptotic genes in peripheral blood leukocytes. HD, IF
76  2008 Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. CHOP, siRNA, TRAIL, XO
77  2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. IHC
78  2008 Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. TRAIL-R2
79  2008 Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. CHOP, ROS, siRNA, TRAIL
80  2008 Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. ---
81  2008 c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. CDDO-Me, JNK, TRAIL
82  2008 CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. CHOP, Flex-Het, siRNA, TRAIL
83  2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. CRT, HPV-16
84  2008 Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. CDDO-Me, CHOP, ER
85  2008 Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. TRAIL
86  2008 Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. HBc, HBV, HBx, HCC
87  2008 Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. YY1
88  2008 Involvement of reactive oxygen species/c-Jun NH(2)-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells. KTA
89  2008 Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. DR4, NSCLC
90  2008 Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. DISC, ROS
91  2008 Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells. CHOP, DR, PKC, siRNA, TRAIL
92  2008 siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli. ---
93  2008 Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. ---
94  2008 Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. TRAIL
95  2008 [Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721]. COX-2, FCM
96  2009 A critical role of PUMA in maintenance of genomic integrity of murine spermatogonial stem cell precursors after genotoxic stress. ---
97  2009 A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL). rTRAIL, sTRAIL, TRAIL
98  2009 Activity of mangosteen xanthones and teleocidin a-2 in death receptor expression enhancement and tumor necrosis factor related apoptosis-inducing ligand assays. AGS, TNF
99  2009 Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa. TRAIL
100  2009 Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells. cyto c, PARP, tBid, TRAIL
101  2009 CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. HUVEC
102  2009 Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells. ---
103  2009 Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. CHOP
104  2009 Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis. AGS, TRAIL
105  2009 Death receptor 5-recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAIL-induced cell death. ---
106  2009 Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis. ---
107  2009 Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. DR4, IR, OS, TRAIL
108  2009 Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. ---
109  2009 Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. TNF, TRAIL
110  2009 Over-expression of Reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP. RTN3, RTNs
111  2009 Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. Cbl, DR4, TRAIL
112  2009 Smac deficiency affects endoplasmic reticulum stress-induced apoptosis in human colon cancer cells. ER, IAPs, Smac, TG
113  2009 Sulindac Sulfide Differentially Induces Apoptosis in Smac-Proficient and -Deficient Human Colon Cancer Cells. IAPs, Smac
114  2009 Suppression of teratocarcinoma growth by soluble TRAIL gene expression driven by the progression-elevated gene-3 promoter. DR4, EC, rPEG, TNF
115  2009 The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. allo-BMT, tGVHD, TRAIL
116  2009 The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. PHHs
117  2009 Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. JNK
118  2009 Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. CHOP, TRAIL
119  2009 X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. FasL, IAP, XIAP
120  2009 [Progress on targeting TRAIL's receptor as antitumor strategy]. DR4, TRAIL
121  2010 1-(3',4',5'-Trimethoxyphenyl)-3-(3'',4''-dimethoxy-2''-hydroxyphenyl)-propane with microtubule-depolymerizing ability induces G2/M phase arrest and apoptosis in HepG2 cells. DP, DR4, MMP, NAC, ROS
122  2010 A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. CSC, PDA
123  2010 alpha-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. alpha-TEA, cFLIPL, TRAIL
124  2010 Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. HNSCC, IHC, LNM
125  2010 Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. AD, CNS
126  2010 Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. ---
127  2010 Death receptor 5-mediated TNFR family signaling pathways modulate gamma-humulene-induced apoptosis in human colorectal cancer HT29 cells. c-FLIP, FADD, PI
128  2010 ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. CHOP
129  2010 FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. PDCD6
130  2010 GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. DR4, Hh, siRNA, TRAIL
131  2010 Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. ART, HIV-1, IRF7, pDC, TNF
132  2010 Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. TRAIL
133  2010 Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. FNAs, TRAIL
134  2010 PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. PBOX-15, TRAIL
135  2010 Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. DLTs, FIH, PK
136  2010 Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). MTD
137  2010 Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells. EP
138  2010 Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. TRAIL
139  2010 Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1. CHOP, ER, Stx1, Stxs, TNF
140  2010 The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. CHOP, HCC, TRAIL
141  2010 Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. CHOP, ER
142  2010 Tricetin, a dietary flavonoid, induces apoptosis through the reactive oxygen species/c-Jun NH2-terminal kinase pathway in human liver cancer cells. TCN
143  2011 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. DMF, HCC, NAC, PBMCs, ROS, TRAIL
144  2011 5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. AFMC, ELISA, FCM, NSCLC, PI, TRAIL
145  2011 A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells. ---
146  2011 Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. ACR, DOX, TRAIL
147  2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. CHOP, NAC
148  2011 An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. FcgammaR
149  2011 B lymphocytes are resistant to death receptor 5-induced apoptosis. SLE
150  2011 c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. PTC, si, TRAIL
151  2011 Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. DOTA-NHS
152  2011 Cycloartane triterpenes isolated from Combretum quadrangulare in a screening program for death-receptor expression enhancing activity. ---
153  2011 Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. c-FLIP, CHOP, TNF
154  2011 Death receptor 5 signaling promotes hepatocyte lipoapoptosis. ER, FFA, TRAIL
155  2011 Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. EMMPRIN
156  2011 Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. ---
157  2011 Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells. DR4, Mapa
158  2011 Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. TNF, TRAIL
159  2011 Interferon-alpha sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway. c-Cbl, TRAIL
160  2011 Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells. CPT
161  2011 Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. PKC, ROS, TRAIL, UDCA
162  2011 Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling. ---
163  2011 Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. ATF3, CHOP, NSCLC, SIRT1, SIRT2
164  2011 Siphonaxanthin, a marine carotenoid from green algae, effectively induces apoptosis in human leukemia (HL-60) cells. ---
165  2011 Structural and functional analysis of the N-terminal region of death receptor 5. DR5-ECD, NTR
166  2011 TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. BBB, BCECs, DOX, DOX-LP, GBM, MDR, TRAIL, TRAIL-LP
167  2011 Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. CIA, LysM.Cre
168  2011 Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. ---
169  2011 Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis. FADD
170  2011 [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC]. LDM, NSCLC, TRAIL
171  2012 Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells. DR4, TRAIL
172  2012 Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2. AMA, NAC, TRAIL
173  2012 Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells. ---
174  2012 Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. TNFR
175  2012 beta-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38. DAPI, MTS, PEITC
176  2012 Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. ROS, TNF
177  2012 Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. DHA
178  2012 Distinct roles of different forms of vitamin E in DHA-induced apoptosis in triple-negative breast cancer cells. alphaT, DHA, ERS, ROS, siRNAs, TNBC
179  2012 Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. HCC, STAT3, TRAIL
180  2012 Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. FACS, FKB, LMS
181  2012 Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathway. DR4, HCV, TRAIL
182  2012 HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. HuR, PDA, TNF, TRAIL, UTR
183  2012 Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. phDR5, TNBC
184  2012 Involvement of de novo ceramide synthesis in gamma-tocopherol and gamma-tocotrienol-induced apoptosis in human breast cancer cells. CHOP, gammaT, p-JNK
185  2012 Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells. DAPI, Smac
186  2012 Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5. CHOP, IOA, NAC, ROS
187  2012 Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. MAPK, TRAIL
188  2012 Managing macrophages in rheumatoid arthritis by reform or removal. RA
189  2012 PKCdelta regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. CHOP, ER, ERK
190  2012 Pomolic acid induces apoptosis in SK-OV-3 human ovarian adenocarcinoma cells through the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways. FITC, PA, TRAIL
191  2012 Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. AML, HDACIs, NF-kappaB, ROS
192  2012 Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway. IL-1beta, qRT-PCR, TRAIL
193  2012 Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. CHOP, GGPP, HMG-CoA, p-JNK, SVA
194  2012 Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. DR4, NSCLC, siRNA, TRAIL
195  2012 Tagged and untagged TRAIL show different activity against tumor cells. ---
196  2012 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). PACS-2, TRAIL
197  2013 APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. DR4, IgG1, scTRAIL-RBD
198  2013 Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. ANT2, Apo2L, TRAIL
199  2013 BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas. GBM, TMZ, TRAIL
200  2013 Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. DC
201  2013 Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress-CCAAT/enhancer binding protein homologous protein dependent mechanism. CHOP, ER, JNK, NHE1, TRAIL
202  2013 Conditionally replicating adenovirus combined with gene-targeted radiotherapy induces apoptosis via TRAIL death receptors in MDA-MB-231 cells. CRAd, ELISA, PI, TNF
203  2013 Degradation of cIAPs contributes to hepatocyte lipoapoptosis. FFAs, PA
204  2013 Effect of enzymatically modified isoquercitrin on preneoplastic liver cell lesions induced by thioacetamide promotion in a two-stage hepatocarcinogenesis model using rats. EMIQ, GST-P, TAA
205  2013 Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles. PDT, TMP
206  2013 Extracellular signal‑regulated kinase inhibition is required for methanol extract of Smilax china L.‑induced apoptosis through death receptor 5 in human oral mucoepidermoid carcinoma cells. ERK, MEC
207  2013 Genista sessilifolia DC. extracts induce apoptosis across a range of cancer cell lines. BAD
208  2013 Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation. NSAIDs, PBMCs, TRAIL
209  2013 Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. IAP, IkappaBalpha-SR, NF-kappaB, TNF-alpha
210  2013 Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. CHOP, ROS, TRAIL
211  2013 Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. TECs
212  2013 Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. CT
213  2013 Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression. CHOP, ER stress, IRE1, OMA, siRNA, TRAIL, XBP1
214  2013 Peroxisome proliferator-activated receptor gamma ligand troglitazone and TRAIL synergistically induce apoptosis. CHOP, PPARgamma, TGZ, TRAIL
215  2013 Phosphorylated IkappaBalpha predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. ABC, DLBCL, TQ
216  2013 Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy. ---
217  2013 Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells. FADD, FLIP, MTT, PARP
218  2013 Sphingoid bases from sea cucumber induce apoptosis in human hepatoma HepG2 cells through p-AKT and DR5. ---
219  2013 The chalcone 2'-hydroxy-4',5'-dimethoxychalcone activates death receptor 5 pathway and leads to apoptosis in human nonsmall cell lung cancer cells. CHOP, HDMC, ROS
220  2013 TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. mCRC
221  2013 Transcriptome analysis of glioma cells for the dynamic response to gamma-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas. IR
222  2013 [Glycosylation inhibitor 2-deoxy-D-glucose sensitizes oral cancer cells to TRAIL-induced apoptosis]. 2-DG, PI, TRAIL
223  2013 [Hypobaric hypoxia increases the expression of death receptor 5 and inhibits that of FLICE-like inhibitory protein in the rat testis]. c-FLIP
224  2014 2'-hydroxyflavanone induces apoptosis of human osteosarcoma 143 B cells by activating the extrinsic TRAIL- and intrinsic mitochondria-mediated pathways. TRAIL
225  2014 A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. DR4, EGFR, TRAIL
226  2014 Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation. SIRT1
227  2014 Death receptor 5 expression is inversely correlated with prostate cancer progression. PCa, PSA, YY1
228  2014 Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. ATO, DR4, MM
229  2014 Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. PEG
230  2014 Expression of selected proteins of the extrinsic and intrinsic pathways of apoptosis in human leukocytes exposed to N-nitrosodimethylamine. NDMA, PBMCs, PMNs, tBid, TRAIL
231  2014 Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity. DR4, ELISA, TRAIL
232  2014 Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer. PET
233  2014 Induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells. IDO, IFN-gamma, NSCLC
234  2014 Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Elk1, ERK, MMTV
235  2014 Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP. AMPK, DR4, FADD, TRAIL
236  2014 Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. ---
237  2014 Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells. MZF1, TRAIL
238  2014 Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. ER, UPR
239  2014 PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. IGF-1R, MM
240  2014 Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. PARP, TRAIL
241  2014 Quinazoline analog HMJ-30 inhibits angiogenesis: involvement of endothelial cell apoptosis through ROS-JNK-mediated death receptor 5 signaling. CAM, HUVECs, JNK, ROS, VEGF
242  2014 Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers. HIC, TRAIL
243  2014 Regulation of the extrinsic apoptotic pathway by microRNA-21 in alcoholic liver injury. HSCs, N-Heps
244  2014 Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. ATF3, ATF4, CCB, ER, TNF, TRAIL, ZER
245  2014 Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. ER, HDACIs
246  2014 Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. ---
247  2014 Synthesis and evaluation of novel isoxazolyl chalcones as potential anticancer agents. EWG
248  2014 The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells. 5-FU
249  2014 The stage-specific testicular germ cell apoptotic response to low-dose radiation and 2,5-hexanedione combined exposure. II: qRT-PCR array analysis reveals dose dependent adaptive alterations in the apoptotic pathway. HD, LCM
250  2014 Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. TRAIL
251  2014 [Application of molecular-targeting cancer prevention to tumor immunity]. PBMCs, TRAIL
252  2015 3,3'-diindolylmethane potentiates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of gastric cancer cells. CHOP, DIM, GRP78, TRAIL
253  2015 A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. VUC
254  2015 A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression. TRAIL
255  2015 Ampelopsin induces apoptosis in HepG2 human hepatoma cell line through extrinsic and intrinsic pathways: Involvement of P38 and ERK. DR4, ROS
256  2015 Anticancer activity of Ashwagandha against human head and neck cancer cell lines. HNSCC, MEAG, tBid
257  2015 Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress. CHOP, DAMPs, ER, ROS, TRAIL, UPR
258  2015 Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases. DR4, RT-PCR, TRAIL, UDCA, XIAP
259  2015 Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke. LAA, OPG, ROC, TRAIL
260  2015 Chaetocin induces endoplasmic reticulum stress response and leads to death receptor 5-dependent apoptosis in human non-small cell lung cancer cells. ER, NSCLC
261  2015 Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers. ATF4, NSCLC, PERK, ROS, TRAIL
262  2015 Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. HDAC3
263  2015 Effect of vitamin E succinate on the expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor in gastric cancer cells and CD4(+) T cells. DR4, TRAIL, VES
264  2015 FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. PTPs, SRB
265  2015 Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. rmhTRAIL, TRAIL
266  2015 Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. ---
267  2015 Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients. COPD, TRAIL
268  2015 Induction of apoptosis by parthenolide in human oral cancer cell lines and tumor xenografts. PTL, tBid
269  2015 Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. TRAIL
270  2015 Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. TRAIL
271  2015 New benzimidazole acridine derivative induces human colon cancer cell apoptosis in vitro via the ROS-JNK signaling pathway. ---
272  2015 NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. DR4
273  2015 Proline Oxidase (POX) as A Target for Cancer Therapy. POX
274  2015 Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. ---
275  2015 Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. MMP-1
276  2015 The enhanced expression of death receptor 5 (DR5) mediated by HBV X protein through NF-kappaB pathway is associated with cell apoptosis induced by (TNF-alpha related apoptosis inducing ligand) TRAIL in hepatoma cells. DR4, HBx, TRAIL
277  2015 The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells. DR4, HSA
278  2015 [Affinity Detection and Quantification of Receptors of TRAIL Based on Their Thermostability]. AP, AP-TRAIL, TRAIL
279  2015 [Screening of anti-human death receptor 5 antibody from a large natural phage antibody library]. scFvs
280  2016 4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation. 4E-BPs
281  2016 A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. HDAC, siRNA, TRAIL
282  2016 A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. TNBC
283  2016 A novel derivative of tetrandrine (H1) induces endoplasmic reticulum stress-mediated apoptosis and prosurvival autophagy in human non-small cell lung cancer cells. c-FLIP, NSCLC
284  2016 Activating Transcription Factor 4 (ATF4)-ATF3-C/EBP Homologous Protein (CHOP) Cascade Shows an Essential Role in the ER Stress-Induced Sensitization of Tetrachlorobenzoquinone-Challenged PC12 Cells to ROS-Mediated Apoptosis via Death Receptor 5 (DR5) Signaling. ATF4, DISC, ER, PCP, TCBQ
285  2016 Activation of TRAIL-DR5 pathway promotes sensorineural degeneration in the inner ear. TNF, TRAIL
286  2016 An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5. DR5TP
287  2016 Analysis of aDR5scFv with Specific Identification and Function. mAb, scFv, sTRAIL
288  2016 Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. APG, DR4, NSCLC
289  2016 Caffeic acid phenethyl ester enhances TRAIL-mediated apoptosis via CHOP-induced death receptor 5 upregulation in hepatocarcinoma Hep3B cells. CAPE, CAPE/TRAIL, CHOP, TRAIL
290  2016 Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. CaM, DISC
291  2016 Combination of Nimbolide and TNF-alpha-Increases Human Colon Adenocarcinoma Cell Death through JNK-mediated DR5 Up- regulation. JNK, MTT
292  2016 Cudrania tricuspidata Stem Extract Induces Apoptosis via the Extrinsic Pathway in SiHa Cervical Cancer Cells. CTS, TRAIL
293  2016 Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. CRC, IAPs, TRAIL
294  2016 Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function. ---
295  2016 Expression of TRAIL and its receptor DR5 and their significance in acute leukemia cells. TRAIL
296  2016 Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5. CM, IR
297  2016 In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. ---
298  2016 Inhibition of gamma-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5. GSIs, T-ALL, TRAIL
299  2016 Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. EVs, NASH, ROCK1
300  2016 Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. TRAIL
301  2016 mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity. CRC
302  2016 Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells. ATF4, ESCC
303  2016 New withanolides with TRAIL-sensitizing effect from Physalis pubescens L. CHOP, RCC, TRAIL
304  2016 Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. TRAIL
305  2016 Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2alpha and inhibits tumor growth. CHOP, HIF, RCC, TRAIL, VHL
306  2016 Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. ---
307  2016 Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade. QC
308  2016 Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study. SCID, TNF
309  2016 Stage-dependent effects of exogenous TRAIL on atherogenesis: role of ER stress-mediated sensitization of macrophage apoptosis. CHOP, ER, TRAIL
310  2016 Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study. DD, DISC, FADD
311  2016 Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. DR4, TRAIL
312  2016 Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction. DR4, NSCLC, TRAIL
313  2016 Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation. ER, ESCC, TRAIL
314  2016 The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation. ---
315  2016 The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. IHC, TNBC
316  2017 A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo. scFv
317  2017 Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. DR4, TNF, TRAIL
318  2017 Anticancer activity of Nelumbo nucifera stamen extract in human colon cancer HCT-116 cells in vitro. Bcl-2, DR4, MMP
319  2017 Apigenin promotes TRAIL-mediated apoptosis regardless of ROS generation. 3-MA, BAF, GSH, NAC, ROS
320  2017 Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells. CaM, DISC, TFP
321  2017 Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo. scFv
322  2017 Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. ER, ROS, TNF
323  2017 Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5. CHOP, TRAIL
324  2017 Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors. ECD, mAb
325  2017 Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis. DcR3, HCC, TRAIL
326  2017 Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. DEX, DOX, DR5-KD, ET, PIF, QC, TNBC
327  2017 Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells. ---
328  2017 Glutamine deprivation sensitizes human breast cancer MDA-MB-231 cells to TRIAL-mediated apoptosis. CHOP, ER, Gln, TRAIL
329  2017 Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells. HCC
330  2017 Inducement of apoptosis by cucurbitacin E, a tetracyclic triterpenes, through death receptor 5 in human cervical cancer cell lines. Cu E
331  2017 Inhibition of NF-kappaB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy. TRAIL
332  2017 Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. Chol, GBM, MbetaCD, TMZ
333  2017 Paraquat induces extrinsic pathway of apoptosis in A549 cells by induction of DR5 and repression of anti-apoptotic proteins, DDX3 and GSK3 expression. DISC, GSK-3, PQ
334  2017 Prodelphinidins isolated from Chinese bayberry leaves induces apoptosis via the p53-dependent signaling pathways in OVCAR-3 human ovarian cancer cells. Bcl-2, OPAs, PCBLs, PPAs, PUMA
335  2017 Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin. NSCLC, TRAIL, TSN
336  2017 Soluble Extracellular Domain of Death Receptor 5 Inhibits TRAIL-Induced Apoptosis by Disrupting Receptor-Receptor Interactions. ECD, TNF, TRAIL
337  2017 Tetraarsenic hexoxide induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt suppression and p38 MAPK activation in SW620 human colon cancer cells. Bcl-2, cdc2, LC3, p38 MAPK, PARP, PI3K, ROS, XIAP
338  2017 The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. EZH2, HOTAIR, TRAIL
339  2017 The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. DUB
340  2017 TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions. DISC, NO, QC, ROS
341  2017 Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5. DR4, TNBC, uPAR
342  2017 Ursodeoxycholic Acid Induces Death Receptor-mediated Apoptosis in Prostate Cancer Cells. DR4, TRAIL, UDCA
343  2017 [Thioridazine Sensitizes Apoptotic Effect of TRAIL in Human Lung Cancer PC9 Cells Through ER Stress Mediated Up-regulation of DR5]. ATF4, CHOP, eIF2alpha, ER, GRP78, PERK, TRAIL
344  2018 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5. AMPK, CHOP, ER, GRP78, TRAIL
345  2018 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L. 4-HBR, 4-HPR, ER, qPCR, RA, TNF
346  2018 A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. FOLR1, OvCa
347  2018 Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux. NSCLC, TRAIL
348  2018 Bile acid-induced apoptosis and bile acid synthesis are reduced by over-expression of Augmenter of Liver Regeneration (ALR) in a STAT3-dependent mechanism. ALR, FOXA2, GCDCA
349  2018 Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. CaM, TNBC
350  2018 Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5. ALT, TNF, TUNEL
351  2018 Chrysanthemulide A induces apoptosis through DR5 upregulation via JNK-mediated autophagosome accumulation in human osteosarcoma cells. CA, JNK, siRNA, TRAIL
352  2018 Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. ER, RIDD, RPAP2, UPR
353  2018 Dasatinib promotes TRAIL-mediated apoptosis by upregulating CHOP-dependent death receptor 5 in gastric cancer. CHOP, GC, TRAIL
354  2018 Directed Change in TNFalpha Specificity to Create DR5 Antagonists. ---
355  2018 Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. Bax, Bcl-2, FADD, HIBD, Sham, TRAIL
356  2018 Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells. PCa, RAB
357  2018 Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. ER, SRF, TRAIL
358  2018 Hypoxia-Inducible Factor 1-alpha (HIF-1alpha) Induces Apoptosis of Human Uterosacral Ligament Fibroblasts Through the Death Receptor and Mitochondrial Pathways. BNIP3, c-FLIP, COL1A1, DcR2, HIF-1alpha, hUSLFs, TRAIL
359  2018 Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation. ATF4, CHOP, TRAIL
360  2018 IRF-5 Promotes Cell Death in CD4T Cells during Chronic Infection. IFN, IRF5, TLR7
361  2018 Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. c-FLIP, FADD, Iri, NAC, ROS, TRAIL
362  2018 Low Molecular Weight Mannogalactofucans Derived from Undaria pinnatifida Induce Apoptotic Death of Human Prostate Cancer Cells In Vitro and In Vivo. LMMGFs, MF
363  2018 Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP. c-FLIP, CHOP, TRAIL
364  2018 miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis. CRC, miR-128, ROS, SIRT1, TRAIL
365  2018 miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). ---
366  2018 Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. DISC, MCPIP1, TRAIL
367  2018 Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily. DR4, TNFR, TRAIL
368  2018 Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway. IH, PIGS, SEM
369  2018 Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. DISC, DR4, PDAC, TNF, TRAIL-R1, TRAIL-R2
370  2018 Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca2+-CaMKII-Sp1 pathway. CaMKII, CHOP, EGTA, ER, ROS, siRNA, TRAIL
371  2019 Apoptotic effect of fluoxetine through the endoplasmic reticulum stress pathway in the human gastric cancer cell line AGS. ER, FLX, ROS
372  2019 Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5. TNBC
373  2019 Artonin E sensitizes TRAIL-induced apoptosis by DR5 upregulation and cFLIP downregulation in TRAIL-refractory colorectal cancer LoVo cells. CRC
374  2019 Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway. AC, mTOR, PI3K, TRAIL
375  2019 BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5. BET, BETi, SPOP
376  2019 Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. TRAIL
377  2019 Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. TRAIL
378  2019 Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. DDLPS, FACS, LPS, PDCs, TRAIL
379  2019 DR5 related autophagy can promote apoptosis in gliomas after irradiation. RAP, TMZ
380  2019 Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells throughthe up-regulation of death receptor 5. FXR, SQSTM
381  2019 Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5. Bcl-2, Bcl-xL, DcR1, GBA, MDR1, NSCLCs, TRAIL, TUNEL, XIAP
382  2019 Glucosamine Enhances TRAIL-Induced Apoptosis in the Prostate Cancer Cell Line DU145. GlcN, TNF
383  2019 Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. TMH
384  2019 Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment. Nbs, TRAIL
385  2019 Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL. IFN
386  2019 Involvement of ERK1/2-mediated ELK1/CHOP/DR5 pathway in 6-(methylsulfinyl)hexyl isothiocyanate-induced apoptosis of colorectal cancer cells. CHOP
387  2019 Methyloleanolate Induces Apoptotic And Autophagic Cell Death Via Reactive Oxygen Species Generation And c-Jun N-terminal Kinase Phosphorylation. 3-MA, ATG5, CQ, LC3BII, MEF
388  2019 p53-Mediated Oxidative Stress Enhances Indirubin-3'-Monoxime-Induced Apoptosis in HCT116 Colon Cancer Cells by Upregulating Death Receptor 5 and TNF-Related Apoptosis-Inducing Ligand Expression. CHOP, ER, I3M, ROS, TNF
389  2019 Prognostic significance of serum soluble DR5 levels in small-cell lung cancer. SCLC, sDR5, VALSG
390  2019 Pseudolaric Acid B Induces Growth Inhibition and Caspase-Dependent Apoptosis on Head and Neck Cancer Cell lines through Death Receptor 5. HNC, PAB
391  2019 Quercetin enhances the antitumor activity of trichostatin A through up-regulation of p300 protein expression in p53 null cancer cells. TSA
392  2019 Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells. siRNA
393  2019 Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer. CSC, MSCs, NSCLC, TNF
394  2019 The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway. BBB, BER, ER, GBM, POH
395  2019 TRAIL-Inspired Multivalent Dextran Conjugates Efficiently Induce Apoptosis upon DR5 Receptor Clustering. DISC, Fc
396  2019 Treatment of acetaminophen-induced liver failure by blocking the death checkpoint protein TRAIL. sDR5-Fc
397  2019 Tubulin couples death receptor 5 to regulate apoptosis. TNF
398  2019 Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines. DR4, NB, TRAIL, XN
399  2020 Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53. ART, ATS, DHA, TRAIL
400  2020 Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats. MI, TNF
401  2020 CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. HDAC, PI3K, TRAIL
402  2020 Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3beta Activation in Cancer Cells. DEX, TRAIL
403  2020 Dissecting Programmed Cell Death with Small Molecules. Hsp90, MLKL, PCD
404  2020 DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. CPT, NP
405  2020 Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. ---
406  2020 Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells. EGCG, TRAIL, TUNEL
407  2020 HIF-1alpha Mediates TRAIL-Induced Neuronal Apoptosis via Regulating DcR1 Expression Following Traumatic Brain Injury. DcR1, HIF, sDR5, TBI, TRAIL
408  2020 Imipridone enhances vascular relaxation via FOXO1 pathway. ACh, ERK, PI3K
409  2020 Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation. DSS, IBD, TNF, TRAIL
410  2020 Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor5 upregulation. TRAIL
411  2020 Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. ---
412  2020 Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Drp1, JNK, NSCLC, TRAIL
413  2020 Microcystin-leucine arginine exposure contributes to apoptosis and follicular atresia in mice ovaries by endoplasmic reticulum stress-upregulated Ddit3. 4-PBA, DDIT3, ER, IRE1, MC-LR, PP2A
414  2020 Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. ER, UPR
415  2020 Molecular mechanisms underlying the effects of the small molecule AMC-04 on apoptosis: Roles of the activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway. ATF4, eIF2alpha, p38 MAPK, ROS, UPR
416  2020 Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. TRAIL
417  2020 ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. ClpP, DRD2, GPCR, TRAIL
418  2020 Quinovic acid purified from medicinal plant Fagonia indica mediates anticancer effects via death receptor 5. QA
419  2020 RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. CRIS, DISC, mCRC, MT
420  2020 ROS-mediated PERK-eIF2alpha-ATF4 pathway plays an important role in arsenite-induced L-02 cells apoptosis via regulating CHOP-DR5 signaling. ATF4, CHOP, DISC, ER, NAC, PERK, ROS
421  2020 Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy. PA
422  2020 Targeting of keloid with TRAIL and TRAIL-R2/DR5. TRAIL
423  2020 Tianma Gouteng Decoction Exerts Cardiovascular Protection by Upregulating OPG and TRAIL in Spontaneously Hypertensive Rats. SHR, TGD, WKY
424  2020 TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. NK, rhTRAIL, TNBC, TRAIL
425  2020 Up-regulation of Death Receptor 5/TRAIL-R2 Mediates Apoptosis Induced by N,N'-[(3,4-dimethoxyphenyl)methylene] Biscinnamide in Cancer Cells. DPMBC
426  2020 YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation. cFLIP, TRAIL
427  2021 A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. PPCR
428  2021 BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. BAP1, DR4, MPM, TRAIL, YY1
429  2021 BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. BET, CRC, ICD, PROTAC, SPOP
430  2021 Bioymifi, a novel mimetic of TNF-related apoptosis-induced ligand (TRAIL), stimulates eryptosis. BMF, COX, RBCs, TRAIL, WB
431  2021 Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. DHCP, SQR, TRAIL
432  2021 Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5. TRAIL, XIAP
433  2021 Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp. RT-qPCR, SKR, TRAIL
434  2021 Designed proteins assemble antibodies into modular nanocages. ACE2, SARS-CoV-2
435  2021 DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment. BCSCs, DLL4, GSIs, mAb, SLNs, TNBC
436  2021 DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. DAPT, DR5-DAPT-SLNs, TNBC
437  2021 Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist. DcR, DR, OPG, TRAIL
438  2021 First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer. GI, PET
439  2021 Glucose deprivation-induced endoplasmic reticulum stress response plays a pivotal role in enhancement of TRAIL cytotoxicity. ATF4, Bax, CHOP, ER, TRAIL
440  2021 LCT-3d Induces Oxidative Stress-Mediated Apoptosis by Upregulating Death Receptor 5 in Gastric Cancer Cells. NAC, Nrf2, ROS
441  2021 Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. ---
442  2021 Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. CI, DIPG, HDACi
443  2021 Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. ADC, ALL, CDX, MMAE, PDX
444  2021 Sodium fluoride activates the extrinsic apoptosis via regulating NOX4/ROS-mediated p53/DR5 signaling pathway in lung cells both in vitro and in vivo. NOX4, ROS, siRNA
445  2021 Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis. c-FLIP, DISC, HSP70, TRAIL
446  2021 The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells. BOZ, TRAIL
447  2021 TRAIL induces proliferation in rodent pancreatic beta cells via AKT activation. DcR1, sTRAIL, TRAIL
448  2021 Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. ---
449  2021 Vanillin oxime inhibits lung cancer cell proliferation and activates apoptosis through JNK/ERK-CHOP pathway. CHOP, TRAIL
450  2022 AF8c, a Multi-Kinase Inhibitor Induces Apoptosis by Activating DR5/Nrf2 via ROS in Colorectal Cancer Cells. CRC, ER, NRF2, ROS
451  2022 CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. ---
452  2022 Co-overexpression of TRAIL and Smac sensitizes MDA-MB-231 cells to radiation through apoptosis depending on mitochondrial pathway. cyt c, Smac, TRAIL
453  2022 Dual role of ERK2/NF-κB signaling in TRAIL sensitivity. TRAIL, TRAIL-R
454  2022 Elevated soluble death receptor 5 can predict poor prognosis in patients with acute respiratory distress syndrome. ARDS, BALF, sRAGE, TNF
455  2022 Enhanced expression of death receptor 5 is responsible for increased cytotoxicity of theophylline in combination with recombinant human TRAIL in MDA-MB-231 breast cancer cells. MMP, rhTRAIL, ROS
456  2022 Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment. CSCs, FasL, NPC, TRAIL
457  2022 Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy. ACT, CAR, COX-2, INDO, NSAID, PGE2, TCR, TRAIL
458  2022 Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells. ATF3, ChIP, HCC, UPR
459  2022 Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells. DR4, ER, ERK, HCC, JNK, LCB, MAPK, TRAIL
460  2022 LncRNA-MEG3 attenuates hyperglycemia-induced damage by enhancing mitochondrial translocation of HSP90A in the primary hippocampal neurons. HG, lncRNA, RIP
461  2022 MicroRNA-148a Inhibits Hepatocellular Carcinoma Cell Growth via Epithelial-to-Mesenchymal Transition and PI3K/AKT Signaling Pathways by Targeting Death Receptor-5. EMT, HCC, miR-148a
462  2022 Molecular Targets of Nimbolide for Anti-Cancer Therapy: An Updated Review. EGF, IGF, JNK, MAPK, NF-kappaBeta, PI3K, TNF-alpha, VEGF, Wnt
463  2022 Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma. ERN-T, IAPs, NSFs, TRAIL
464  2022 Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy. BMDMs, DN, EVs, LPC, LRG1, TECs, TRAIL